Abstract
The tumor necrosis factor-α (TNF-α) antagonists infliximab, adalimumab, and etanercept have been approved for treatment of inflammatory bowel disease (IBD). We describe a rare manifestation of a demyelinating neuropathy affecting the peripheral nervous system in a patient on Infliximab for the treatment of Crohn’s disease following progression of his disease.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
